3D Medicines (HKSE:01244) COGS-to-Revenue : 0.08 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines COGS-to-Revenue?

3D Medicines's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$23.8 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$308.9 Mil.

3D Medicines's COGS to Revenue for the six months ended in Dec. 2023 was 0.08.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. 3D Medicines's Gross Margin % for the six months ended in Dec. 2023 was 92.28%.

3D Medicines COGS-to-Revenue Historical Data

The historical data trend for 3D Medicines's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines COGS-to-Revenue Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

0.07

0.08

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial			-	0.07	0.07	0.08	0.08

3D Medicines COGS-to-Revenue Calculation

3D Medicines's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	53.695	/	694.494
	=	0.08

3D Medicines's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	23.834	/	308.879
	=	0.08

3D Medicines (HKSE:01244) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

3D Medicines's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	23.834 / 308.879
	=	92.28 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

3D Medicines COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of 3D Medicines's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines